Background: EUROPSO (European Federation of Psoriasis Patient Associations) undertook a Europe-wide survey examining quality of life and patients’perspectives on treatment and their disease. Objectives: To explore pa...Background: EUROPSO (European Federation of Psoriasis Patient Associations) undertook a Europe-wide survey examining quality of life and patients’perspectives on treatment and their disease. Objectives: To explore patients’perspectives of psoriasis on their lifestyle and well-being and to gain insight into the effectiveness of and satisfaction with currently available therapies for psoriasis. Methods: Self-administered questionnaires (n = 50 500) were mailed to members of psoriasis patient associations in Belgium, the Czech Republic, Finland, France, Germany, Italy and the Netherlands. Results: Responses were received from 18 386 patients (36%), of whom 17 990 had psoriasis. Mean age at onset of psoriasis was 30.5 years, 59%of respondents had self-reported moderate to severe psoriasis (3%or greater body surface area involvement) and 30%had been diagnosed with psoriatic arthritis. The mean Psoriasis Disability Index score was 12.2 (25%of the maximum score), increasing to 21 (44%) in patients with more than 10%body surface area involvement. The greatest impact was on activities of daily living, especially affecting clothing choice, bathing routine and sporting activities. Overall, 77%replied that psoriasis was a problem or a significant problem. While patients were satisfied with the information and care from their dermatologist (40%highly satisfied), available treatment options were less satisfactory, with over 70%reporting only low tomoderate satisfaction. Conclusions: This is the largest survey of people with psoriasis in Europe and shows that psoriasis has a profound impact on quality of life.展开更多
文摘Background: EUROPSO (European Federation of Psoriasis Patient Associations) undertook a Europe-wide survey examining quality of life and patients’perspectives on treatment and their disease. Objectives: To explore patients’perspectives of psoriasis on their lifestyle and well-being and to gain insight into the effectiveness of and satisfaction with currently available therapies for psoriasis. Methods: Self-administered questionnaires (n = 50 500) were mailed to members of psoriasis patient associations in Belgium, the Czech Republic, Finland, France, Germany, Italy and the Netherlands. Results: Responses were received from 18 386 patients (36%), of whom 17 990 had psoriasis. Mean age at onset of psoriasis was 30.5 years, 59%of respondents had self-reported moderate to severe psoriasis (3%or greater body surface area involvement) and 30%had been diagnosed with psoriatic arthritis. The mean Psoriasis Disability Index score was 12.2 (25%of the maximum score), increasing to 21 (44%) in patients with more than 10%body surface area involvement. The greatest impact was on activities of daily living, especially affecting clothing choice, bathing routine and sporting activities. Overall, 77%replied that psoriasis was a problem or a significant problem. While patients were satisfied with the information and care from their dermatologist (40%highly satisfied), available treatment options were less satisfactory, with over 70%reporting only low tomoderate satisfaction. Conclusions: This is the largest survey of people with psoriasis in Europe and shows that psoriasis has a profound impact on quality of life.
